+ Watch ANIK
on My Watchlist
The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
what a horror show. they cant get anything right! all the products being wasted. morons @ the helm! how do you not know for sure that the FDA would not allow you to manufacture opthalmic products without all equipment in a new facility? What they gave a thumbs up & then changed their mind?! so much loss of capital with this company. they wasted elevess or hydrelle or whatever they call it now. couldn't reach a marketing agreement with Galderma! Then coapt systems, which went bankrupt. for crying out loud coapt systems was even smaller than anika!Then monovisc. They were gonna work on the salesforce starting last qtr. what are the odds they even had resume's! Should have never invested in this comapny! never! never!Oh! the horror! the horror! I wonder how they'll respond to this. i hope the 4th qtr will have had some earnings good news. BUT I RATHER DOUBT IT!!!Please don't believe this stock has any value. for eternity. somebody will buy this for 5 bucks a share! how much cash these guys made on stockoptions, is unbelievable! i need patience like ATVI, but i've gone thru this for 4 years now.what a loss. but i've got to stick it thru for another 2 years of excuses!
okay 1 year later, now year # 5 of my original purchase of ANIK. I finally believe this company has turned the corner. The beating for the stock not staying above $12 was due to the FDA not wanting to give them quick track approval for Monovisc. This is a single injection viscosupplement. It's alreadry approved & sold widely in Europe. Now, the FDA has all of a sudden slowed the process down, that's for all companies. But Anik is seeking the help of J&J, whose subsidiary Depuy Mitek markets orthovisc ( 3 injections) to help with FDA approval. But the critical point is that management got rid of all the useless agendas of elevess ( or whatever it's called now) & focused on it's core product. Their market share stands @ 14% & growing. Secondly, the Anika s.r.l, their italian subsidiary has turned the corner & is beginning to contribute, profitably. They had the highest of earnings, revenue, this years, sans shennanigans. We may be looking at a company that hits 75 million + in revenue this year & begin to get noticed by the bigger boys.Chuck royce & associates own this also. So, though I may not be adding anymore, I'd like to retract my harsher comments from earlier last year. I didn't think management would stop doodling around & simply focus on core growth & the rest would follow. But they got it. They finally got it. I hope they continue. While they work on Monovisc, they are doing clinical studies with cingal, which if it works out will be stellar. I wasn't expecting cost controls, Ankia s.r.l to work out in such fashion. Suffice to say, doubling your eps, sans shennanigans, is a masterful work. Wow, this company may yet turn into a diamond in the rough that I thought it would be 5 years ago. Only problem, any delays or notifications of delay from FDA crushes the stock, even though it has absolutely no issue from a revenue/ cash flow/ eps metric. So, i gently recant all the stuff I said earlier. i've convinced myself that Anik is a 20-30 dollar stock 3-5 years from now!!!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions